Physician profile
Brian L Ackerman
NPI 1235517913
$12,698.73
in general payments reported to CMS, 2019-2025
20 companies · $3,080 in 2025
The $3,080 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $40.30 · 2021: $441 · 2022: $1,692 · 2023: $3,305 · 2024: $3,780 · 2025: $3,080.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,853 · Education: $312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,853.39 |
| Education | $312.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,373.15 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,909.29 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,719.64 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $1,399.77 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Alkermes, INC. | $1,018.16 | 2019-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $832.13 | 2024-2025 | Fanapt |
| Lundbeck LLC | $665.69 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $556.88 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $432.80 | 2019-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $313.96 | 2019-2025 | Trintellix |
| Axsome Therapeutics, INC. | $284.32 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $221.96 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $193.69 | 2023-2024 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $162.66 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $156.50 | 2024-2025 | Qelbree |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $155.91 | 2022-2024 | Quviviq |
| Corium, LLC | $130.19 | 2022-2025 | Azstarys |
| Sage Therapeutics, LLC | $101.41 | 2023-2025 | Zurzuvae |
| Collegium Pharmaceutical, INC. | $57.55 | 2025 | Jornay Pm |
| Bausch Health US, LLC | $13.07 | 2023 | Aplenzin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Ackerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.